203 related articles for article (PubMed ID: 25580923)
1. Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series.
Miodownik C; Bergman J; Lerner PP; Kreinin A; Lerner V
Clin Neuropharmacol; 2015; 38(1):26-9. PubMed ID: 25580923
[TBL] [Abstract][Full Text] [Related]
2. Donepezil as Add-on Treatment for Resistant Obsessive-Compulsive Disorder: Retrospective Case Series.
Bergman J; Miodownik C; Lerner PP; Miodownik E; Shulkin A; Lerner V
Clin Neuropharmacol; 2016; 39(4):194-6. PubMed ID: 27223667
[TBL] [Abstract][Full Text] [Related]
3. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.
Metin O; Yazici K; Tot S; Yazici AE
Hum Psychopharmacol; 2003 Aug; 18(6):463-7. PubMed ID: 12923825
[TBL] [Abstract][Full Text] [Related]
4. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?
Ersche KD; Cumming P; Craig KJ; Müller U; Fineberg NA; Bullmore ET; Robbins TW
J Psychopharmacol; 2012 Jun; 26(6):887-90. PubMed ID: 21746752
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
Mohr N; Vythilingum B; Emsley RA; Stein DJ
Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
[TBL] [Abstract][Full Text] [Related]
10. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series.
Dell'Osso B; Mundo E; Altamura AC
CNS Spectr; 2006 Nov; 11(11):879-83; quiz 885. PubMed ID: 17075559
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.
Oulis P; Mourikis I; Konstantakopoulos G
Int Clin Psychopharmacol; 2011 Jul; 26(4):221-4. PubMed ID: 21460732
[TBL] [Abstract][Full Text] [Related]
14. Hyperpigmentation with amisulpride.
Mendhekar DN
Aust N Z J Psychiatry; 2009 Jan; 43(1):88. PubMed ID: 19086350
[No Abstract] [Full Text] [Related]
15. Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.
Akyol Ardic U; Ercan ES; Kutlu A; Yuce D; Ipci M; Inci SB
Child Psychiatry Hum Dev; 2017 Oct; 48(5):699-704. PubMed ID: 27812841
[TBL] [Abstract][Full Text] [Related]
16. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
Pessina E; Albert U; Bogetto F; Maina G
Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study.
Maina G; Vitalucci A; Gandolfo S; Bogetto F
J Clin Psychiatry; 2002 Jan; 63(1):38-43. PubMed ID: 11838624
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
